Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
  • Home
  • ICR Divisions
  • Breast Cancer Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?

Thumbnail
Date
2008-02
ICR Author
Martin, Lesley-Ann
Dowsett, Mitch
Johnston, Stephen
Smith, Ian
Author
Johnston, SRD
Leary, A
Martin, L-A
Smith, IE
Dowsett, M
Type
Conference Proceeding
Metadata
Show full item record
Abstract
Acquired resistance to endocrine therapies has severely limited their long-term effectiveness in breast cancer. In recent years a clear rationale has developed for combining signal transduction inhibitors (STIs) with endocrine therapies to delay the emergence of acquired resistance and enhance endocrine responsiveness. A variety of biologic agents have been developed to target key proteins along the EGFR, HER2, MAPK, and P13K/Akt signal transduction cascades. While several of these agents have shown early promise in selected breast cancer models, translating these data into convincing clinical results has been generally disappointing to date. By applying more rigorous trial design and tumor selection criteria to future trials, it is much more likely that adding the new generation of targeted therapies can fulfill its promise in enhancing endocrine responsiveness and our ability to treat breast cancer patients.
URI
https://repository.icr.ac.uk/handle/internal/2049
DOI
https://doi.org/10.1002/cncr.23190
Collections
  • Breast Cancer Research
  • Clinical Studies
  • Molecular Pathology
Subject
Animals
Humans
Breast Neoplasms
Disease Models, Animal
Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Drug Resistance, Neoplasm
Research team
Endocrine Therapy Resistance
Medicine (RMH Smith Cunningham)
Endocrinology
Language
eng
License start date
2008-02
Citation
Cancer, 2008, 112 (3 Suppl), pp. 710 - 717

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.